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S276 Poster Session IIMethods:We performed a retrospective analysis of our patients
with CLL/Pro-lymphocytic leukemia (PLL) who underwent Al-
SCT at our center between August 1989 and February 2009.
The objective of this study is to evaluate the overall survival
(OS), relapse free survival (RFS), acute and chronic graft versus
host disease (aGVHD, cGVHD). We also compared the inten-
sity of conditioning regimens (conventional: CIC Vs reduced:
RIC), donor type, (matched sibling: MSD vs matched unre-
lated: MUD), graft source (bone marrow: BM vs peripheral
blood: PB) and their impact on OS, RFS, aGVHD and
cGVHD.
Results:There are 59 patients available for review. Patients char-
acteristics are listed in table 1. There were a variety of condition-
ing regimens; for the CIC, 36 pts. received Busulfan based
regimens and 10 pts. Total Body Irradiation based regimens, for
the RIC 13 pts. received different fludarabine based regimens.
Donor types were 48 MSD and 11 MUD. Source was BM in
27 and PB in 32 pts. Most (43/59 pts) received CyA-MTX as
the GvHD prophylaxis but 12 and 4 pts. received Mycophenolate
and Campath with CyA respectively. The median follow up is 45
months (7-237). The median survival time is 115 months with a 5
year survival probability of 57% (95% CI: 0.43-0.68). OS was not
statistically significantly different when comparing type of condi-
tioning or graft source, however a significant improvement in
OS with MSD type over MUD, (P value5 0.0007). The 3-year
RFS is 48% (95% CI: 0.35-0.60) with no statistically significant
difference according to regimen intensity and graft source, with
a significant superior outcome for MSD Vs MUD (P val-
ue5 0.002). Grade 2-4 aGvHD was seen in 40 cases. The cumu-
lative rates of aGvHD 2-4 are not different between the
conditioning, donor type and graft source. Forty-one cases
(68%) experienced cGvHD (18% limited,50% extensive) with no
difference according to regimen intensity and donor type, al-
though a significantly increased incidence in the PB group (P val-
ue5 0.03). Causes of death include infection (40%), GVHD
(33%), relapse (18%) and VOD (9%).
Conclusions: Acceptable survival post Al-SCT is possible in CLL
although TRM is significant. This retrospective analysis demon-
strates inferior survival for MUD recipients and similar outcomes
when comparing RIC and CIC regimens.
Table 1. Patients characteristicsPts studied , n. 59
Diagnosis : CLL / PLL 54 / 5
Mean age (range), y 46 (27-67)
Gender (F /M), n. 19 / 40
Number of prior regimens, mean (range) 4 (1-9)
Prior Purine analogue 84 %
Prior Rituximab 11 %318
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Severe aplastic anemia (SAA) in children is a rare and serious dis-
ease. The best potential cure is allogeneic hematopoietic stem cell
transplantation (SCT). Our objective herein was to review the out-
come of all children who received SCT for a diagnosis of SAA be-
tween 1998-2008 in the Hospital for Sick Children, Toronto.
Fifty-eight children were included in the study. Median age at
SCT was 10.1 years (range 1.6-17 yrs). Median time from diagnosis
to SCT was 8.8 months (range 1-142 months). Stem cell source was
related in 38; living unrelated in 18 and 2 patients received cord pro-
genitor stem cells.
Twenty-seven patients received immunosuppressant therapy
prior to SCT. Conditioning regimen for the related donors in-cluded cyclophosphamide and antithymocyte globulin (ATG).
For the unrelated, either a single dose total body irradiation
(TBI) 200 cGy or fludarabine was added. Overall survival for
the whole group was 84%. In a univaraite analysis, factors af-
fecting survival were: stem cell source (related 90%; unrelated
71%); type of SAA (idiopathic 90%; post hepatitis or drug re-
lated 70%; possible hereditary 60%); previous immunossupres-
sive therapy and multiple transfusions (of 10 patients who
died, 8 were treated with 1 or 2 courses of immunossupressive
therapy and 6 of them had more than 20 blood transfusions be-
fore SCT).
Incidence of acute and chronic graft-versus host disease (GVHD)
were 29% and 14% respectively with 6 out of 8 patients with chronic
GVHDwere recipient of unrelated donors. Ten patients died due to
transplant related mortality (TRM) and seven were recipient of un-
related donors. Causes of death were: sepsis, severe VOD, CMV in-
fection and multiorgan failure.
Long term chimerism testing showed 54% of the patients con-
tinued to have full donor status, 22% are stable mixed chimerism
and 4% with decreased chimerism; 15% suffered engraftment fail-
ure (5%-primary and 10%-secondary) and 5% of patients died be-
fore engraftment and were not evaluable for engraftment. Of the 9
patients with primary and secondary graft failure 6 had unrelated
donor.
In conclusion: Our results suggest that factors affecting prognosis
of children with SAA treated with SCT are: etiology of SAA, previ-
ous immunosuppressant therapy, multiple transfusions and type of
donor. Furthermore, engraftment failure continues to be a problem
in particular for recipient of unrelated donors.319
RELATION OF TNFA, TNFB AND TNFRII GENE POLYMORPHISMS TO OUT-
COMES AFTER UNRELATED HAEMATOPOIETIC CELL TRANSPLANTATION
WITHIN CHINESE POPULATION
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Background: The genes code TNFa (TNFA), TNFb (TNFB) and
TNF receptor II (TNFRII) contain multiple single nucleotide poly-
morphisms (SNPs). The present study was designed to test associa-
tion of these genes polymorphisms with outcomes after unrelated
HSCT within Chinese population.
Methods: A total of 138 pairs of donors and recipients, who
had undergone HSCT from 2001 to 2009 at our center, were
tested for TNFA-1031(T.C), -863(C.A), -857(C.T),
-238(G.A), TNFB + 252(A.G) and TNFRII codon 196
(T.G) genotypes.
Results: (1) Recipients and/or donors with TNFA-857 C/C geno-
type or TNFB + 252 G allele-positive had a higher incidence of
aGVHD (P\0.05). TNFRII 196 T/T genotype in donors side
or recipients side showed a stronger trend toward development of
aGVHD (in donor side: P5 0.028; in recipient side: P5 0.086).
When these effects were analyzed only in 96 pairs of HLA matched
cases, donor and/or recipient TNFA-857 and TNFB + 252 geno-
type also affected aGVHD incidence. The influence of TNFRII
genotype was not significant except the recipient type showed
a trend (P5 0.074).The genotypes of TNFA -1031, -863 and
-238 were not found to be associated with the risk of aGVHD.
(2) TNFA-857, TNFB + 252 and TNFRII 196 polymorphic fea-
tures, together with other factors were subjected to multivariate
analysis for aGVHD. Myeloablative conditioning(RR5 3.771,
P5 0.004), donor with TNFA-857C/C genotype (RR5 2.29,
P5 0.006) and recipient with TNFB + 252 G allele-positive
(RR5 1.789, P5 0.036) were found to significantly contribute to
the development of aGVHD. Donor-recipient gender was found
to be a less significant factor (P5 0.079). As to grade II-IV
aGVHD, myeloablative conditioning (RR5 3.929, P5 0.022),
HLA mismatching (RR5 1.691, P5 0.048) and donor with
TNFA-857 C/C genotype (RR5 3.748, P5 0.002) were found to
